Invitae Corporation (NVTAQ)
| Market Cap | 85.95K |
| Revenue (ttm) | 481.58M -7.4% |
| Net Income | -1.44B |
| EPS | -5.57 |
| Shares Out | 286.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,678 |
| Open | 0.0002 |
| Previous Close | 0.0004 |
| Day's Range | n/a |
| 52-Week Range | 0.0001 - 1.1400 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NVTAQ
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invit... [Read more]
News
Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
SAN FRANCISCO , Aug. 14, 2025 /PRNewswire/ -- Citizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was le...
Labcorp Finalizes Acquisition of Select Assets of Invitae
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and co...
Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients
– Program provides accessible and affordable testing for pediatric epilepsy patients – – Genetic and clinical insights from test results to strengthen Invitae's rare disease database – SAN FRANCISCO ,...
New Research Demonstrates the Importance of Genetic Testing for Many Cancers Not Currently Covered by Clinical Guidelines
– Study findings to be presented at the 2024 ASCO Annual Meeting find hereditary risk for gastric and lung cancers, among others, underscoring the need for broader genetic testing – SAN FRANCISCO , Ma...
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after the genetic ...
Labcorp Announces Winning Bid for Select Assets of Invitae
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N...
Invitae Enters into Agreement with Labcorp for Sale of Business
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's As...
Invitae Publishes its Environmental, Social and Governance (ESG) Report
– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRA...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics compan...
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
– An Invitae-developed innovative approach to help reduce variants of uncertain significance – SAN FRANCISCO , March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company,...
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
SAN FRANCISCO , March 6, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and ...
Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
– Announcing Invitae Generation™, a high-quality variant detection and classification platform – SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical g...
Genetic test maker Invitae files for bankruptcy protection in US
Softbank-backed genetic test maker Invitae said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy court and intends to pursue a sale process.
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
– Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients – SAN FRANCISCO , Feb. 13, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a l...
NYSE to Commence Delisting Proceedings Against Invitae Corporation (NVTA)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Inv...
Medical test maker Invitae prepares for bankruptcy - WSJ
Medical test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported on Monday, according to people familiar with the matter.
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage bi...
Natera Acquires Reproductive Health Assets from Invitae
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetic...
Invitae Completes Sale of Reproductive Health Assets to Natera
SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include...
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
– Maintains Minority Equity Stake in Ciitizen – – Anticipated Total Cash Savings of Approximately $90-100 Million on an Annualized Basis – SAN FRANCISCO , Dec. 13, 2023 /PRNewswire/ -- Invitae (NYSE...
Aranscia Acquires YouScript from Invitae
SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)--Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today annou...
Invitae Reports Third Quarter 2023 Financial Results
Reported revenue of $121.2 million, a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4% Gross margin of 32....
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient...
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
SAN FRANCISCO , Nov. 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday, Novemb...
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
– Findings set to enhance patient care and reduce uncertainty in test results as clinicians advance precision healthcare for hereditary disease – SAN FRANCISCO , Oct. 25, 2023 /PRNewswire/ -- Invit...